<div id="readability-page-1"><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>An announcement from Medtide, Inc. Class H ( (HK:3880) ) is now available. Medtide Inc. has received a filing notice from the China Securities Regulatory Commission confirming completion of the regulatory filing for its H share full circulation plan, paving the way for the conversion of its domestic shares into H shares and their listing in Hong Kong. While the detailed implementation plan for the conversion and listing has yet to be finalized and remains subject to additional procedures and approvals from the CSRC, the Hong Kong Stock Exchange and other regulators, the move signals further progress in enhancing the company’s share liquidity and aligning its capital structure with Hong Kong capital market practices, though shareholders are cautioned about the remaining regulatory and execution risks. The most recent analyst rating on (HK:3880) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Medtide, Inc. Class H stock, see the HK:3880 Stock Forecast page. More about Medtide, Inc. Class H Medtide Inc. is a joint stock company incorporated in the People’s Republic of China with limited liability and listed in Hong Kong under stock code 3880. The company has a board composed of executive, non-executive and independent non-executive directors, reflecting a typical governance structure for a Hong Kong-listed mainland issuer, though the specific industry and main products or services are not disclosed in this announcement. Average Trading Volume: 145,385 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$3.52B </div>

03880

159570

159837

159849

516930

520500

516500

513120

300347

Medtide, Inc. has received confirmation from the China Securities Regulatory Commission for its H share full circulation plan, allowing the conversion of domestic shares into H shares for listing in Hong Kong. While the implementation plan is pending further approvals, this move aims to enhance share liquidity and align with Hong Kong market practices. Current analyst rating for Medtide (HK:3880) is a Hold with a price target of HK$38.00. The company has a market cap of HK$3.52B and an average trading volume of 145,385 shares.

Medtide Secures CSRC Filing for H Share Full Circulation Plan